Cargando…
Are breast cancer patients with suboptimal adherence to cardiovascular treatment more likely to discontinue adjuvant endocrine therapy? Competing risk survival analysis in a nationwide cohort of postmenopausal women
BACKGROUND: High rates of discontinuation undermine the effectiveness of adjuvant endocrine therapy (AET) among hormone-receptive breast cancer patients. Patient prognosis also relies on the successful management of cardiovascular risk, which affects a high proportion of postmenopausal women. As wit...
Autores principales: | Artignan, Juliette, Capmas, Perrine, Panjo, Henri, Constantinou, Panayotis, Pelletier-Fleury, Nathalie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675896/ https://www.ncbi.nlm.nih.gov/pubmed/38001491 http://dx.doi.org/10.1186/s12916-023-03156-3 |
Ejemplares similares
-
Adherence behaviours in breast cancer patients at risk of cardiovascular disease
por: Artignan, J, et al.
Publicado: (2023) -
Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer
por: Güth, U, et al.
Publicado: (2008) -
Adjuvant endocrine therapy for postmenopausal breast cancer in the era of aromatase inhibitors: an update
por: Mokbel, Ramia, et al.
Publicado: (2006) -
Effectiveness of gefitinib in combination with methotrexate in the treatment of ectopic pregnancy
por: Capmas, Perrine, et al.
Publicado: (2015) -
Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation
por: Smith, Karen Lisa, et al.
Publicado: (2022)